Industry Research Reports
Home > Reports > Service & Software > Global Neurodegenerative Disease CDMO Market Research Report 2025
Global Neurodegenerative Disease CDMO Market Research Report 2025
Industry: Service & Software
Published Date: 2025-07-11
Pages: 86 Pages
Report ld: 4788680
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Neurodegenerative Disease CDMO Market Size(US$)
CAGR 2025-2031
6.9%
Market Size,2031
USD 1,149
Million
Market Snapshot
Market Size in 2025 (Value)
US$ 770 million
Market Forecast in 2031(Value)
US$ 1,149 million
CAGR
6.9%
Years Considered
2020-2031
Base Year
2025
Forecast Period
2025-2031
Source: Secondary research, interviews with experts, and QYResearch analysis
The global market for Neurodegenerative Disease CDMO was valued at US$ 735 million in the year 2024 and is projected to reach a revised size of US$ 1149 million by 2031, growing at a CAGR of 6.9% during the forecast period.
Neurodegenerative disease CDMO is a contract research and development and manufacturing organization that focuses on the field of neurodegenerative diseases and provides pharmaceutical companies and scientific research institutions with a full range of services from drug discovery, preclinical research to commercial production. Its core is to develop innovative therapies for the complex pathologies of diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease (such as abnormal protein aggregation, neuroinflammation, mitochondrial dysfunction, etc.) by integrating professional technology platforms such as neuroscience, protein engineering, cell therapy, and gene therapy. It also relies on a deep understanding of the special requirements of regulatory agencies such as the FDA and EMA (such as biomarker verification and long-term safety assessment) to ensure that research and development and production meet international standards, ultimately accelerating the launch of drugs for the treatment of neurodegenerative diseases.
North American market for Neurodegenerative Disease CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Neurodegenerative Disease CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Neurodegenerative Disease CDMO in Alzheimer's Disease is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Neurodegenerative Disease CDMO include AC Immune, Alterity Therapeutics, Biogen, Charles River Laboratories, Coave Therapeutics, Sysmex Corp, Donanemab, Eisai, Fujirebio Holdings, GenSight Biologics, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Neurodegenerative Disease CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurodegenerative Disease CDMO.
The Neurodegenerative Disease CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neurodegenerative Disease CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neurodegenerative Disease CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
MARKET SEGMENTATION
By Company
- AC Immune
- Alterity Therapeutics
- Biogen
- Charles River Laboratories
- Coave Therapeutics
- Sysmex Corp
- Donanemab
- Eisai
- Fujirebio Holdings
- GenSight Biologics
- Neuropore Therapies
- Nevrargenics
- PPD
- Samsung Biologics
- Sanofi(Vigil Neuroscience)
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Small Molecule Drug CDMO
- Biopharmaceutical CDMO
- Cell and Gene Therapy (CGT) CDMO
- OtherS
Segment by Application
- Alzheimer's Disease
- Parkinson's Disease
- Huntington's Disease
- Amyotrophic Lateral Sclerosis (ALS)
- Multiple System Atrophy (MSA)
- Progressive Supranuclear Palsy (PSP)
- Others
CHAPTER OUTLINE
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neurodegenerative Disease CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurodegenerative Disease CDMO Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Small Molecule Drug CDMO
1.2.3 Biopharmaceutical CDMO
1.2.4 Cell and Gene Therapy (CGT) CDMO
1.2.5 OtherS
1.3 Market by Application
1.3.1 Global Neurodegenerative Disease CDMO Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Alzheimer's Disease
1.3.3 Parkinson's Disease
1.3.4 Huntington's Disease
1.3.5 Amyotrophic Lateral Sclerosis (ALS)
1.3.6 Multiple System Atrophy (MSA)
1.3.7 Progressive Supranuclear Palsy (PSP)
1.3.8 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neurodegenerative Disease CDMO Market Perspective (2020-2031)
2.2 Global Neurodegenerative Disease CDMO Growth Trends by Region
2.2.1 Global Neurodegenerative Disease CDMO Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Neurodegenerative Disease CDMO Historic Market Size by Region (2020-2025)
2.2.3 Neurodegenerative Disease CDMO Forecasted Market Size by Region (2026-2031)
2.3 Neurodegenerative Disease CDMO Market Dynamics
2.3.1 Neurodegenerative Disease CDMO Industry Trends
2.3.2 Neurodegenerative Disease CDMO Market Drivers
2.3.3 Neurodegenerative Disease CDMO Market Challenges
2.3.4 Neurodegenerative Disease CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neurodegenerative Disease CDMO Players by Revenue
3.1.1 Global Top Neurodegenerative Disease CDMO Players by Revenue (2020-2025)
3.1.2 Global Neurodegenerative Disease CDMO Revenue Market Share by Players (2020-2025)
3.2 Global Top Neurodegenerative Disease CDMO Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Neurodegenerative Disease CDMO Revenue
3.4 Global Neurodegenerative Disease CDMO Market Concentration Ratio
3.4.1 Global Neurodegenerative Disease CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Disease CDMO Revenue in 2024
3.5 Global Key Players of Neurodegenerative Disease CDMO Head office and Area Served
3.6 Global Key Players of Neurodegenerative Disease CDMO, Product and Application
3.7 Global Key Players of Neurodegenerative Disease CDMO, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurodegenerative Disease CDMO Breakdown Data by Type
4.1 Global Neurodegenerative Disease CDMO Historic Market Size by Type (2020-2025)
4.2 Global Neurodegenerative Disease CDMO Forecasted Market Size by Type (2026-2031)
5 Neurodegenerative Disease CDMO Breakdown Data by Application
5.1 Global Neurodegenerative Disease CDMO Historic Market Size by Application (2020-2025)
5.2 Global Neurodegenerative Disease CDMO Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Neurodegenerative Disease CDMO Market Size (2020-2031)
6.2 North America Neurodegenerative Disease CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Neurodegenerative Disease CDMO Market Size by Country (2020-2025)
6.4 North America Neurodegenerative Disease CDMO Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neurodegenerative Disease CDMO Market Size (2020-2031)
7.2 Europe Neurodegenerative Disease CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Neurodegenerative Disease CDMO Market Size by Country (2020-2025)
7.4 Europe Neurodegenerative Disease CDMO Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Neurodegenerative Disease CDMO Market Size (2020-2031)
8.2 Asia-Pacific Neurodegenerative Disease CDMO Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Neurodegenerative Disease CDMO Market Size by Region (2020-2025)
8.4 Asia-Pacific Neurodegenerative Disease CDMO Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Neurodegenerative Disease CDMO Market Size (2020-2031)
9.2 Latin America Neurodegenerative Disease CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Neurodegenerative Disease CDMO Market Size by Country (2020-2025)
9.4 Latin America Neurodegenerative Disease CDMO Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neurodegenerative Disease CDMO Market Size (2020-2031)
10.2 Middle East & Africa Neurodegenerative Disease CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Neurodegenerative Disease CDMO Market Size by Country (2020-2025)
10.4 Middle East & Africa Neurodegenerative Disease CDMO Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AC Immune
11.1.1 AC Immune Company Details
11.1.2 AC Immune Business Overview
11.1.3 AC Immune Neurodegenerative Disease CDMO Introduction
11.1.4 AC Immune Revenue in Neurodegenerative Disease CDMO Business (2020-2025)
11.1.5 AC Immune Recent Development
11.2 Alterity Therapeutics
11.2.1 Alterity Therapeutics Company Details
11.2.2 Alterity Therapeutics Business Overview
11.2.3 Alterity Therapeutics Neurodegenerative Disease CDMO Introduction
11.2.4 Alterity Therapeutics Revenue in Neurodegenerative Disease CDMO Business (2020-2025)
11.2.5 Alterity Therapeutics Recent Development
11.3 Biogen
11.3.1 Biogen Company Details
11.3.2 Biogen Business Overview
11.3.3 Biogen Neurodegenerative Disease CDMO Introduction
11.3.4 Biogen Revenue in Neurodegenerative Disease CDMO Business (2020-2025)
11.3.5 Biogen Recent Development
11.4 Charles River Laboratories
11.4.1 Charles River Laboratories Company Details
11.4.2 Charles River Laboratories Business Overview
11.4.3 Charles River Laboratories Neurodegenerative Disease CDMO Introduction
11.4.4 Charles River Laboratories Revenue in Neurodegenerative Disease CDMO Business (2020-2025)
11.4.5 Charles River Laboratories Recent Development
11.5 Coave Therapeutics
11.5.1 Coave Therapeutics Company Details
11.5.2 Coave Therapeutics Business Overview
11.5.3 Coave Therapeutics Neurodegenerative Disease CDMO Introduction
11.5.4 Coave Therapeutics Revenue in Neurodegenerative Disease CDMO Business (2020-2025)
11.5.5 Coave Therapeutics Recent Development
11.6 Sysmex Corp
11.6.1 Sysmex Corp Company Details
11.6.2 Sysmex Corp Business Overview
11.6.3 Sysmex Corp Neurodegenerative Disease CDMO Introduction
11.6.4 Sysmex Corp Revenue in Neurodegenerative Disease CDMO Business (2020-2025)
11.6.5 Sysmex Corp Recent Development
11.7 Donanemab
11.7.1 Donanemab Company Details
11.7.2 Donanemab Business Overview
11.7.3 Donanemab Neurodegenerative Disease CDMO Introduction
11.7.4 Donanemab Revenue in Neurodegenerative Disease CDMO Business (2020-2025)
11.7.5 Donanemab Recent Development
11.8 Eisai
11.8.1 Eisai Company Details
11.8.2 Eisai Business Overview
11.8.3 Eisai Neurodegenerative Disease CDMO Introduction
11.8.4 Eisai Revenue in Neurodegenerative Disease CDMO Business (2020-2025)
11.8.5 Eisai Recent Development
11.9 Fujirebio Holdings
11.9.1 Fujirebio Holdings Company Details
11.9.2 Fujirebio Holdings Business Overview
11.9.3 Fujirebio Holdings Neurodegenerative Disease CDMO Introduction
11.9.4 Fujirebio Holdings Revenue in Neurodegenerative Disease CDMO Business (2020-2025)
11.9.5 Fujirebio Holdings Recent Development
11.10 GenSight Biologics
11.10.1 GenSight Biologics Company Details
11.10.2 GenSight Biologics Business Overview
11.10.3 GenSight Biologics Neurodegenerative Disease CDMO Introduction
11.10.4 GenSight Biologics Revenue in Neurodegenerative Disease CDMO Business (2020-2025)
11.10.5 GenSight Biologics Recent Development
11.11 Neuropore Therapies
11.11.1 Neuropore Therapies Company Details
11.11.2 Neuropore Therapies Business Overview
11.11.3 Neuropore Therapies Neurodegenerative Disease CDMO Introduction
11.11.4 Neuropore Therapies Revenue in Neurodegenerative Disease CDMO Business (2020-2025)
11.11.5 Neuropore Therapies Recent Development
11.12 Nevrargenics
11.12.1 Nevrargenics Company Details
11.12.2 Nevrargenics Business Overview
11.12.3 Nevrargenics Neurodegenerative Disease CDMO Introduction
11.12.4 Nevrargenics Revenue in Neurodegenerative Disease CDMO Business (2020-2025)
11.12.5 Nevrargenics Recent Development
11.13 PPD
11.13.1 PPD Company Details
11.13.2 PPD Business Overview
11.13.3 PPD Neurodegenerative Disease CDMO Introduction
11.13.4 PPD Revenue in Neurodegenerative Disease CDMO Business (2020-2025)
11.13.5 PPD Recent Development
11.14 Samsung Biologics
11.14.1 Samsung Biologics Company Details
11.14.2 Samsung Biologics Business Overview
11.14.3 Samsung Biologics Neurodegenerative Disease CDMO Introduction
11.14.4 Samsung Biologics Revenue in Neurodegenerative Disease CDMO Business (2020-2025)
11.14.5 Samsung Biologics Recent Development
11.15 Sanofi(Vigil Neuroscience)
11.15.1 Sanofi(Vigil Neuroscience) Company Details
11.15.2 Sanofi(Vigil Neuroscience) Business Overview
11.15.3 Sanofi(Vigil Neuroscience) Neurodegenerative Disease CDMO Introduction
11.15.4 Sanofi(Vigil Neuroscience) Revenue in Neurodegenerative Disease CDMO Business (2020-2025)
11.15.5 Sanofi(Vigil Neuroscience) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
TABLE OF FIGURES
List of Tables
Table 1. Global Neurodegenerative Disease CDMO Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Small Molecule Drug CDMO
Table 3. Key Players of Biopharmaceutical CDMO
Table 4. Key Players of Cell and Gene Therapy (CGT) CDMO
Table 5. Key Players of OtherS
Table 6. Global Neurodegenerative Disease CDMO Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Neurodegenerative Disease CDMO Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Neurodegenerative Disease CDMO Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Neurodegenerative Disease CDMO Market Share by Region (2020-2025)
Table 10. Global Neurodegenerative Disease CDMO Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Neurodegenerative Disease CDMO Market Share by Region (2026-2031)
Table 12. Neurodegenerative Disease CDMO Market Trends
Table 13. Neurodegenerative Disease CDMO Market Drivers
Table 14. Neurodegenerative Disease CDMO Market Challenges
Table 15. Neurodegenerative Disease CDMO Market Restraints
Table 16. Global Neurodegenerative Disease CDMO Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Neurodegenerative Disease CDMO Market Share by Players (2020-2025)
Table 18. Global Top Neurodegenerative Disease CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disease CDMO as of 2024)
Table 19. Ranking of Global Top Neurodegenerative Disease CDMO Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Neurodegenerative Disease CDMO Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Neurodegenerative Disease CDMO, Headquarters and Area Served
Table 22. Global Key Players of Neurodegenerative Disease CDMO, Product and Application
Table 23. Global Key Players of Neurodegenerative Disease CDMO, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Neurodegenerative Disease CDMO Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Neurodegenerative Disease CDMO Revenue Market Share by Type (2020-2025)
Table 27. Global Neurodegenerative Disease CDMO Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Neurodegenerative Disease CDMO Revenue Market Share by Type (2026-2031)
Table 29. Global Neurodegenerative Disease CDMO Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Neurodegenerative Disease CDMO Revenue Market Share by Application (2020-2025)
Table 31. Global Neurodegenerative Disease CDMO Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Neurodegenerative Disease CDMO Revenue Market Share by Application (2026-2031)
Table 33. North America Neurodegenerative Disease CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Neurodegenerative Disease CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Neurodegenerative Disease CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Neurodegenerative Disease CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Neurodegenerative Disease CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Neurodegenerative Disease CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Neurodegenerative Disease CDMO Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Neurodegenerative Disease CDMO Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Neurodegenerative Disease CDMO Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Neurodegenerative Disease CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Neurodegenerative Disease CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Neurodegenerative Disease CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Neurodegenerative Disease CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Neurodegenerative Disease CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Neurodegenerative Disease CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 48. AC Immune Company Details
Table 49. AC Immune Business Overview
Table 50. AC Immune Neurodegenerative Disease CDMO Product
Table 51. AC Immune Revenue in Neurodegenerative Disease CDMO Business (2020-2025) & (US$ Million)
Table 52. AC Immune Recent Development
Table 53. Alterity Therapeutics Company Details
Table 54. Alterity Therapeutics Business Overview
Table 55. Alterity Therapeutics Neurodegenerative Disease CDMO Product
Table 56. Alterity Therapeutics Revenue in Neurodegenerative Disease CDMO Business (2020-2025) & (US$ Million)
Table 57. Alterity Therapeutics Recent Development
Table 58. Biogen Company Details
Table 59. Biogen Business Overview
Table 60. Biogen Neurodegenerative Disease CDMO Product
Table 61. Biogen Revenue in Neurodegenerative Disease CDMO Business (2020-2025) & (US$ Million)
Table 62. Biogen Recent Development
Table 63. Charles River Laboratories Company Details
Table 64. Charles River Laboratories Business Overview
Table 65. Charles River Laboratories Neurodegenerative Disease CDMO Product
Table 66. Charles River Laboratories Revenue in Neurodegenerative Disease CDMO Business (2020-2025) & (US$ Million)
Table 67. Charles River Laboratories Recent Development
Table 68. Coave Therapeutics Company Details
Table 69. Coave Therapeutics Business Overview
Table 70. Coave Therapeutics Neurodegenerative Disease CDMO Product
Table 71. Coave Therapeutics Revenue in Neurodegenerative Disease CDMO Business (2020-2025) & (US$ Million)
Table 72. Coave Therapeutics Recent Development
Table 73. Sysmex Corp Company Details
Table 74. Sysmex Corp Business Overview
Table 75. Sysmex Corp Neurodegenerative Disease CDMO Product
Table 76. Sysmex Corp Revenue in Neurodegenerative Disease CDMO Business (2020-2025) & (US$ Million)
Table 77. Sysmex Corp Recent Development
Table 78. Donanemab Company Details
Table 79. Donanemab Business Overview
Table 80. Donanemab Neurodegenerative Disease CDMO Product
Table 81. Donanemab Revenue in Neurodegenerative Disease CDMO Business (2020-2025) & (US$ Million)
Table 82. Donanemab Recent Development
Table 83. Eisai Company Details
Table 84. Eisai Business Overview
Table 85. Eisai Neurodegenerative Disease CDMO Product
Table 86. Eisai Revenue in Neurodegenerative Disease CDMO Business (2020-2025) & (US$ Million)
Table 87. Eisai Recent Development
Table 88. Fujirebio Holdings Company Details
Table 89. Fujirebio Holdings Business Overview
Table 90. Fujirebio Holdings Neurodegenerative Disease CDMO Product
Table 91. Fujirebio Holdings Revenue in Neurodegenerative Disease CDMO Business (2020-2025) & (US$ Million)
Table 92. Fujirebio Holdings Recent Development
Table 93. GenSight Biologics Company Details
Table 94. GenSight Biologics Business Overview
Table 95. GenSight Biologics Neurodegenerative Disease CDMO Product
Table 96. GenSight Biologics Revenue in Neurodegenerative Disease CDMO Business (2020-2025) & (US$ Million)
Table 97. GenSight Biologics Recent Development
Table 98. Neuropore Therapies Company Details
Table 99. Neuropore Therapies Business Overview
Table 100. Neuropore Therapies Neurodegenerative Disease CDMO Product
Table 101. Neuropore Therapies Revenue in Neurodegenerative Disease CDMO Business (2020-2025) & (US$ Million)
Table 102. Neuropore Therapies Recent Development
Table 103. Nevrargenics Company Details
Table 104. Nevrargenics Business Overview
Table 105. Nevrargenics Neurodegenerative Disease CDMO Product
Table 106. Nevrargenics Revenue in Neurodegenerative Disease CDMO Business (2020-2025) & (US$ Million)
Table 107. Nevrargenics Recent Development
Table 108. PPD Company Details
Table 109. PPD Business Overview
Table 110. PPD Neurodegenerative Disease CDMO Product
Table 111. PPD Revenue in Neurodegenerative Disease CDMO Business (2020-2025) & (US$ Million)
Table 112. PPD Recent Development
Table 113. Samsung Biologics Company Details
Table 114. Samsung Biologics Business Overview
Table 115. Samsung Biologics Neurodegenerative Disease CDMO Product
Table 116. Samsung Biologics Revenue in Neurodegenerative Disease CDMO Business (2020-2025) & (US$ Million)
Table 117. Samsung Biologics Recent Development
Table 118. Sanofi(Vigil Neuroscience) Company Details
Table 119. Sanofi(Vigil Neuroscience) Business Overview
Table 120. Sanofi(Vigil Neuroscience) Neurodegenerative Disease CDMO Product
Table 121. Sanofi(Vigil Neuroscience) Revenue in Neurodegenerative Disease CDMO Business (2020-2025) & (US$ Million)
Table 122. Sanofi(Vigil Neuroscience) Recent Development
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
Table 126. Authors List of This Report
List of Figures
Figure 1. Neurodegenerative Disease CDMO Picture
Figure 2. Global Neurodegenerative Disease CDMO Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Neurodegenerative Disease CDMO Market Share by Type: 2024 VS 2031
Figure 4. Small Molecule Drug CDMO Features
Figure 5. Biopharmaceutical CDMO Features
Figure 6. Cell and Gene Therapy (CGT) CDMO Features
Figure 7. OtherS Features
Figure 8. Global Neurodegenerative Disease CDMO Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Neurodegenerative Disease CDMO Market Share by Application: 2024 VS 2031
Figure 10. Alzheimer's Disease Case Studies
Figure 11. Parkinson's Disease Case Studies
Figure 12. Huntington's Disease Case Studies
Figure 13. Amyotrophic Lateral Sclerosis (ALS) Case Studies
Figure 14. Multiple System Atrophy (MSA) Case Studies
Figure 15. Progressive Supranuclear Palsy (PSP) Case Studies
Figure 16. Others Case Studies
Figure 17. Neurodegenerative Disease CDMO Report Years Considered
Figure 18. Global Neurodegenerative Disease CDMO Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 19. Global Neurodegenerative Disease CDMO Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 20. Global Neurodegenerative Disease CDMO Market Share by Region: 2024 VS 2031
Figure 21. Global Neurodegenerative Disease CDMO Market Share by Players in 2024
Figure 22. Global Neurodegenerative Disease CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 23. The Top 10 and 5 Players Market Share by Neurodegenerative Disease CDMO Revenue in 2024
Figure 24. North America Neurodegenerative Disease CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. North America Neurodegenerative Disease CDMO Market Share by Country (2020-2031)
Figure 26. United States Neurodegenerative Disease CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Canada Neurodegenerative Disease CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Europe Neurodegenerative Disease CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Europe Neurodegenerative Disease CDMO Market Share by Country (2020-2031)
Figure 30. Germany Neurodegenerative Disease CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. France Neurodegenerative Disease CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. U.K. Neurodegenerative Disease CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Italy Neurodegenerative Disease CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Russia Neurodegenerative Disease CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Ireland Neurodegenerative Disease CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific Neurodegenerative Disease CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Neurodegenerative Disease CDMO Market Share by Region (2020-2031)
Figure 38. China Neurodegenerative Disease CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Japan Neurodegenerative Disease CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. South Korea Neurodegenerative Disease CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Southeast Asia Neurodegenerative Disease CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. India Neurodegenerative Disease CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Australia & New Zealand Neurodegenerative Disease CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Latin America Neurodegenerative Disease CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Latin America Neurodegenerative Disease CDMO Market Share by Country (2020-2031)
Figure 46. Mexico Neurodegenerative Disease CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Brazil Neurodegenerative Disease CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Middle East & Africa Neurodegenerative Disease CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Middle East & Africa Neurodegenerative Disease CDMO Market Share by Country (2020-2031)
Figure 50. Israel Neurodegenerative Disease CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Saudi Arabia Neurodegenerative Disease CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. UAE Neurodegenerative Disease CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. AC Immune Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2020-2025)
Figure 54. Alterity Therapeutics Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2020-2025)
Figure 55. Biogen Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2020-2025)
Figure 56. Charles River Laboratories Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2020-2025)
Figure 57. Coave Therapeutics Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2020-2025)
Figure 58. Sysmex Corp Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2020-2025)
Figure 59. Donanemab Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2020-2025)
Figure 60. Eisai Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2020-2025)
Figure 61. Fujirebio Holdings Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2020-2025)
Figure 62. GenSight Biologics Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2020-2025)
Figure 63. Neuropore Therapies Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2020-2025)
Figure 64. Nevrargenics Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2020-2025)
Figure 65. PPD Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2020-2025)
Figure 66. Samsung Biologics Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2020-2025)
Figure 67. Sanofi(Vigil Neuroscience) Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2020-2025)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
Which companies rank high in the global Neurodegenerative Disease CDMO market?
The top companies in the global Neurodegenerative Disease CDMO market are AC Immune、Alterity Therapeutics、Biogen.
What was the global market size of Neurodegenerative Disease CDMO in 2031?
What was the global market size of Neurodegenerative Disease CDMO in 2025?
What is the annual compound growth rate of the global Neurodegenerative Disease CDMO market size from 2025 to 2031?
Which region is expected to have the highest market share?
Related Reports
Global Neurodegenerative Disease CDMO Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Neurodegenerative Disease CDMO market is projected to grow from US$ 770 million in 2025 to US$ 1220 million by 2032, at a CAGR of 6.9% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-03-12
Pages: 133
USD 4900.00
(Single User License)
Global Neurodegenerative Disease CDMO Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Neurodegenerative Disease CDMO market size was US$ 770 million in 2025 and is forecast to reach a readjusted size of US$ 1220 million by 2032 with a CAGR of 6.9% during the forecast period 2026-2032.
Published Date: 2026-03-12
Pages: 98
USD 4250.00
(Single User License)
Global Neurodegenerative Disease CDMO Market Research Report 2026
The global Neurodegenerative Disease CDMO market was valued at US$ 770 million in 2025 and is anticipated to reach US$ 1220 million by 2032, at a CAGR of 6.9% from 2026 to 2032.
Published Date: 2026-03-12
Pages: 112
USD 2900.00
(Single User License)
Neurodegenerative Disease CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Neurodegenerative Disease CDMO was estimated to be worth US$ 770 million in 2025 and is projected to reach US$ 1220 million, growing at a CAGR of 6.9% from 2026 to 2032.
Published Date: 2026-03-09
Pages: 110
USD 3950.00
(Single User License)
Global Neurodegenerative Disease CDMO Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Neurodegenerative Disease CDMO market size was US$ 735 million in 2024 and is forecast to a readjusted size of US$ 1149 million by 2031 with a CAGR of 6.9% during the forecast period 2025-2031.
Published Date: 2025-07-11
Pages: 99
USD 4250.00
(Single User License)
Neurodegenerative Disease CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Neurodegenerative Disease CDMO was estimated to be worth US$ 735 million in 2024 and is forecast to a readjusted size of US$ 1149 million by 2031 with a CAGR of 6.9% during the forecast period 2025-2031.
Published Date: 2025-07-11
Pages: 118
USD 3950.00
(Single User License)
Global Neurodegenerative Disease CDMO Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Neurodegenerative Disease CDMO market is projected to grow from US$ 735 million in 2024 to US$ 1149 million by 2031, at a CAGR of 6.9% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-07-11
Pages: 140
USD 4900.00
(Single User License)
Global Neurodegenerative Disease CDMO Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Neurodegenerative Disease CDMO market is projected to grow from US$ 770 million in 2025 to US$ 1220 million by 2032, at a CAGR of 6.9% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-03-12
Pages: 133
USD 4900.00 (Single User License)Global Neurodegenerative Disease CDMO Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Neurodegenerative Disease CDMO market size was US$ 770 million in 2025 and is forecast to reach a readjusted size of US$ 1220 million by 2032 with a CAGR of 6.9% during the forecast period 2026-2032.
Published: 2026-03-12
Pages: 98
USD 4250.00 (Single User License)Global Neurodegenerative Disease CDMO Market Research Report 2026
The global Neurodegenerative Disease CDMO market was valued at US$ 770 million in 2025 and is anticipated to reach US$ 1220 million by 2032, at a CAGR of 6.9% from 2026 to 2032.
Published: 2026-03-12
Pages: 112
USD 2900.00 (Single User License)Neurodegenerative Disease CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Neurodegenerative Disease CDMO was estimated to be worth US$ 770 million in 2025 and is projected to reach US$ 1220 million, growing at a CAGR of 6.9% from 2026 to 2032.
Published: 2026-03-09
Pages: 110
USD 3950.00 (Single User License)Global Neurodegenerative Disease CDMO Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Neurodegenerative Disease CDMO market size was US$ 735 million in 2024 and is forecast to a readjusted size of US$ 1149 million by 2031 with a CAGR of 6.9% during the forecast period 2025-2031.
Published: 2025-07-11
Pages: 99
USD 4250.00 (Single User License)Neurodegenerative Disease CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Neurodegenerative Disease CDMO was estimated to be worth US$ 735 million in 2024 and is forecast to a readjusted size of US$ 1149 million by 2031 with a CAGR of 6.9% during the forecast period 2025-2031.
Published: 2025-07-11
Pages: 118
USD 3950.00 (Single User License)Global Neurodegenerative Disease CDMO Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Neurodegenerative Disease CDMO market is projected to grow from US$ 735 million in 2024 to US$ 1149 million by 2031, at a CAGR of 6.9% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-07-11
Pages: 140
USD 4900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 2900.00
USD 4350.00
USD 5800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now